Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial September 13, 2021
RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels September 9, 2021
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS September 9, 2021
Inovia Capital Partner and Former RIM CFO and COO Dennis Kavelman Joins BenchSci Board of Directors September 9, 2021
Flywire Announces Flywire Forward, a Virtual Event Focused on the Future of FinTech September 9, 2021
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies September 9, 2021
Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets September 8, 2021